about
Using continuous data on tumour measurements to improve inference in phase II cancer studies.The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.Effective incorporation of biomarkers into phase II trialsRandomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialDesigning phase II trials in cancer: a systematic review and guidance.Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialRandomized phase II trials: time for a new era in clinical trial designShortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.Randomized phase II trials: a long-term investment with promising returnsStrengthening Interactions between Statisticians and Collaborators: Objectives and Sample SizesRandomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemiaMixed response and time-to-event endpoints for multistage single-arm phase II designConservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemSequential design of phase II-III cancer trials.Covariate-adjusted borrowing of historical control data in randomized clinical trials.2015 Guidance on cancer immunotherapy development in early-phase clinical studies.Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.Do single-arm trials have a role in drug development plans incorporating randomised trials?Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.Estimation of renal cell carcinoma treatment effects from disease progression modelingConsiderations in the design of clinical trials for pediatric acute lymphoblastic leukemia.Phase II clinical trials in oncology: are we hitting the target?Assessing oncologic benefit in clinical trials of immunotherapy agents.Clinical trial end points for high-grade glioma: the evolving landscape.Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.The relationship between labial vibrotactile detection and pure-tone hearing thresholds in healthy, ageing adults.Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.More randomization in phase II trials: necessary but not sufficient.Design choices for small-scale phase II trials with non-inferiority (NI) intention.Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.A proof of concept phase II non-inferiority criterion.Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.
P2860
Q30649937-6DE8BDA7-B0DB-4425-8071-89575B3CBB6AQ33732581-4C37F16A-DDA6-40AF-89D5-E27F4E4FD3F1Q33806007-C61D2266-A3B7-4386-A39A-378A9A96D0E6Q33813448-A357A792-369C-4A13-BA2E-053A984BC1CDQ33870594-C4930EEE-2711-4498-971F-D89D217EDB8FQ33915071-10AA689A-E96E-4A8F-AC5C-B26C74EF48ECQ33945307-494AE23F-4642-4C2A-B8C7-7C60455D17D5Q33997879-8DCF297E-F753-4FA6-984C-EE21462E30BEQ34137050-E9DBA22A-EBB8-498F-924D-2047EEA14B58Q34193514-E4C28B1C-A4DA-4976-A4D6-9AE22EC5B049Q34587714-FB3B3923-077F-42FA-BB5E-10F1947B0ABFQ34976755-0DBC6185-08E8-4B2D-B3E2-1A7930FAA219Q35115259-81BF45DA-A0A4-4367-8856-34B2D75D9F69Q35545901-9E16B6E1-71C1-4EE7-B033-73A7D31D55F7Q35669875-B7BA1BFA-E427-404D-B887-453B8656B8A9Q35700578-F97DE897-494F-4DBD-8A14-3609B3C4E355Q35795658-4436B57B-15B8-42E8-8841-36E79FEA0D2EQ35797280-3875C7D3-5FAD-4A80-B9BD-70DE732F9078Q35940107-201F2FCF-57E7-4764-9FEC-E553455E79B4Q36385882-DB3A0D3D-27B9-4505-9B5C-4CE968D58EBDQ36467378-FE6AA0C4-F87A-466F-B471-D5C7D4871756Q36678241-EB2B5AE1-4680-4DA0-AABA-C61B5AB0EA2BQ36866317-73440E16-E9E2-4654-AC93-A5E5B79C17C8Q37000193-7028E64F-3BF4-49D2-932C-998A83C1EDF7Q37217573-E02773D3-E204-4535-9451-A1B8479B8644Q37327945-D9294959-9681-498C-BBDE-2A5100AA9353Q37705422-7937F232-85FF-41B2-AADC-3EC4233A62D5Q37710860-4D9A334C-A860-42BE-9974-07199CB2BA93Q37839482-98C1CE45-8B0C-46F8-82FD-A3F17DEBD07FQ38611303-F9BADD3D-430A-4304-9550-ED5BB0B41436Q38914323-441F8485-E68D-4B7D-8C38-5CC75FC6605CQ39502355-A36A4B34-3A7A-4DC8-8C04-41366ABC16E5Q42828526-0A306D03-48C7-4ED3-BD27-09D5D172E5B9Q46744737-BEF271BF-80D3-4D5E-A935-64196008B9A4Q48240873-6EA8A322-3FEB-43DE-BCA7-287CEAF2AF95Q49665167-3F66C8E0-C1FD-4778-B08F-5F4B7AA348E6Q51081422-CB7A13F8-29BA-4CA6-A6DE-B938F360101DQ51599166-CDA3A925-255E-426A-86B6-3C90E2A4DF94Q53083460-5E791313-2FED-4034-8E25-6603D6C87EEFQ53153700-66934E97-0897-4BFF-A26F-B725EA44A792
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized phase II designs.
@en
Randomized phase II designs.
@nl
type
label
Randomized phase II designs.
@en
Randomized phase II designs.
@nl
prefLabel
Randomized phase II designs.
@en
Randomized phase II designs.
@nl
P2093
P2860
P1476
Randomized phase II designs
@en
P2093
John Crowley
Larry Rubinstein
Michael Leblanc
P2860
P304
P356
10.1158/1078-0432.CCR-08-2031
P407
P577
2009-03-10T00:00:00Z